A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Trial Details

NCT ID
NCT07020221
Phase
PHASE1 / PHASE2
Sponsor
Verastem, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • VS-7375
  • Cetuximab
  • Carboplatin + Pemetrexed + Pembrolizumab
  • Gemcitabine
  • Gemcitabine + Nab-paclitaxel
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Individuals ≥18 years of age.
  • Agreement to sign and date an informed consent form (ICF) approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
  • Histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →